Literature DB >> 24823635

Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma.

Josep M Llovet1.   

Abstract

Focal amplifications in 6p21 containing the VEGFA locus occur in 7%-10% of hepatocellular carcinoma (HCC). A recent paper describes how VEGF-A stimulates paracrine secretion of hepatocyte growth factor by stromal cells, which induces tumor progression. HCC patients with VEGFA amplification are distinctly sensitive to sorafenib.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24823635      PMCID： PMC4071286          DOI： 10.1016/j.ccr.2014.04.019

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  9 in total

1.  Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

Authors:  Jordi Bruix; Jean-Luc Raoul; Morris Sherman; Vincenzo Mazzaferro; Luigi Bolondi; Antonio Craxi; Peter R Galle; Armando Santoro; Michel Beaugrand; Angelo Sangiovanni; Camillo Porta; Guido Gerken; Jorge A Marrero; Andrea Nadel; Michael Shan; Marius Moscovici; Dimitris Voliotis; Josep M Llovet
Journal:  J Hepatol       Date:  2012-06-19       Impact factor: 25.083

2.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

3.  Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

Authors:  Derek Y Chiang; Augusto Villanueva; Yujin Hoshida; Judit Peix; Philippa Newell; Beatriz Minguez; Amanda C LeBlanc; Diana J Donovan; Swan N Thung; Manel Solé; Victoria Tovar; Clara Alsinet; Alex H Ramos; Jordi Barretina; Sasan Roayaie; Myron Schwartz; Samuel Waxman; Jordi Bruix; Vincenzo Mazzaferro; Azra H Ligon; Vesna Najfeld; Scott L Friedman; William R Sellers; Matthew Meyerson; Josep M Llovet
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

Review 4.  Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning.

Authors:  Augusto Villanueva; Josep M Llovet
Journal:  Nat Rev Clin Oncol       Date:  2014-01-07       Impact factor: 66.675

5.  Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Carol E A Peña; Chetan D Lathia; Michael Shan; Gerold Meinhardt; Jordi Bruix
Journal:  Clin Cancer Res       Date:  2012-02-28       Impact factor: 12.531

6.  Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening.

Authors:  Eric T Sawey; Maia Chanrion; Chunlin Cai; Guanming Wu; Jianping Zhang; Lars Zender; Alice Zhao; Ronald W Busuttil; Herman Yee; Lincoln Stein; Dorothy M French; Richard S Finn; Scott W Lowe; Scott Powers
Journal:  Cancer Cell       Date:  2011-03-08       Impact factor: 31.743

Review 7.  Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design.

Authors:  Josep M Llovet; Virginia Hernandez-Gea
Journal:  Clin Cancer Res       Date:  2014-03-03       Impact factor: 12.531

8.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

9.  Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma.

Authors:  Cécile Guichard; Giuliana Amaddeo; Sandrine Imbeaud; Yannick Ladeiro; Laura Pelletier; Ichrafe Ben Maad; Julien Calderaro; Paulette Bioulac-Sage; Mélanie Letexier; Françoise Degos; Bruno Clément; Charles Balabaud; Eric Chevet; Alexis Laurent; Gabrielle Couchy; Eric Letouzé; Fabien Calvo; Jessica Zucman-Rossi
Journal:  Nat Genet       Date:  2012-05-06       Impact factor: 38.330
  9 in total
  29 in total

Review 1.  New knowledge of the mechanisms of sorafenib resistance in liver cancer.

Authors:  Yan-Jing Zhu; Bo Zheng; Hong-Yang Wang; Lei Chen
Journal:  Acta Pharmacol Sin       Date:  2017-03-27       Impact factor: 6.150

Review 2.  Assessment of clinical and radiological response to sorafenib in hepatocellular carcinoma patients.

Authors:  Rodolfo Sacco; Valeria Mismas; Antonio Romano; Marco Bertini; Michele Bertoni; Graziana Federici; Salvatore Metrangolo; Giuseppe Parisi; Emanuele Tumino; Giampaolo Bresci; Luca Giacomelli; Sara Marceglia; Irene Bargellini
Journal:  World J Hepatol       Date:  2015-01-27

3.  Animal model studies indicate a candidate biomarker for sorafenib treatment of hepatocellular carcinoma.

Authors:  Elad Horwitz; Ilan Stein; Yinon Ben-Neriah; Eli Pikarsky
Journal:  Mol Cell Oncol       Date:  2014-10-30

Review 4.  Hepatocyte ploidy and pathological mutations in hepatocellular carcinoma: impact on oncogenesis and therapeutics.

Authors:  Taiji Yamazoe; Taizo Mori; Sachiyo Yoshio; Tatsuya Kanto
Journal:  Glob Health Med       Date:  2020-10-31

Review 5.  Natural interferon-beta treatment for patients with chronic hepatitis C in Japan.

Authors:  Reina Sasaki; Tatsuo Kanda; Shingo Nakamoto; Yuki Haga; Masato Nakamura; Shin Yasui; Xia Jiang; Shuang Wu; Makoto Arai; Osamu Yokosuka
Journal:  World J Hepatol       Date:  2015-05-18

Review 6.  Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out.

Authors:  Hong Sun; Man-Sheng Zhu; Wen-Rui Wu; Xiang-De Shi; Lei-Bo Xu
Journal:  World J Hepatol       Date:  2014-12-27

7.  The Anti-Colon Cancer Effects of Essential Oil of Curcuma phaeocaulis Through Tumour Vessel Normalisation.

Authors:  Yewen Feng; Lu Deng; Hengrui Guo; Yumin Zhao; Fu Peng; Gang Wang; Chenghao Yu
Journal:  Front Oncol       Date:  2021-10-26       Impact factor: 6.244

Review 8.  Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis.

Authors:  Haruhiko Takeda; Atsushi Takai; Tadashi Inuzuka; Hiroyuki Marusawa
Journal:  J Gastroenterol       Date:  2016-10-06       Impact factor: 7.527

9.  Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling.

Authors:  Hao Wang; Wei Hou; Aldeb Perera; Carlee Bettler; Jordan R Beach; Xianzhong Ding; Jun Li; Mitchell F Denning; Asha Dhanarajan; Scott J Cotler; Cara Joyce; Jun Yin; Fowsiyo Ahmed; Lewis R Roberts; Wei Qiu
Journal:  Cell Rep       Date:  2021-02-23       Impact factor: 9.423

10.  pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma.

Authors:  Jun Li; Lehua Shi; Xiaofeng Zhang; Bin Sun; Yefa Yang; Naijian Ge; Huiying Liu; Xia Yang; Lei Chen; Haihua Qian; Mengchao Wu; Zhengfeng Yin
Journal:  Oncotarget       Date:  2016-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.